Akèy › Kansè Poumon ki pa ti selil › Pennsylvania › Reading
Etid klinik pou Kansè Poumon ki pa ti selil nan Reading, PA
9 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Reading (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Reading Hospital, West Reading · 1 mi lwen
- Ephrata Cancer Center, Ephrata · 17 mi lwen
- Sechler Family Cancer Center, Lebanon · 26 mi lwen
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Reading Hospital, West Reading · 1 mi lwen
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- McGlinn Cancer Institute Reading Hospital, West Reading · 1 mi lwen
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Reading Hospital - McGlinn Cancer Institute, West Reading · 1 mi lwen
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Ephrata Cancer Center, Ephrata · 17 mi lwen
- Sechler Family Cancer Center, Lebanon · 26 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Ephrata Cancer Center, Ephrata · 17 mi lwen
- Sechler Family Cancer Center, Lebanon · 26 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Ephrata Cancer Center, Ephrata · 17 mi lwen
- Sechler Family Cancer Center, Lebanon · 26 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Ephrata Cancer Center, Ephrata · 17 mi lwen
- Sechler Family Cancer Center, Lebanon · 26 mi lwen
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Ephrata Cancer Center, Ephrata · 17 mi lwen
- Sechler Family Cancer Center, Lebanon · 26 mi lwen
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
Lòt etid nan Reading
- Kansè poumon11 etid
- Leksemi mieloïd egi5 etid
- Kansè nan tete5 etid
- Twoub Somnolans Eksestif5 etid
- Kansè pwostat4 etid
- Kansè (tout kalite)4 etid
- Kansè kolorektal3 etid
- Nakolepsi3 etid
- Twoub dòmi3 etid
- Fatig3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.